Anti-DARPP32 antibody-immunopositive inclusions in the brain of patients with multiple system atrophy

Clinical Neuropathology

Volumn 27, Issue 5, 2008, Pages 309-316

  Honjo, Y ^a   Shirakashi, Y ^a   Kawamoto, Y ^a   Akiguchi, I ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cdk5; DARPP32; GCI; MSA

Indexed keywords

CYCLIN DEPENDENT KINASE 5; PHOSPHOPROTEIN DARPP 32; PHOSPHOPROTEIN DARPP 32 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTE; CAUDATE NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME SUBSTRATE; FEMALE; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEOCORTEX; NEUROPATHOLOGY; OLIGODENDROGLIA; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PURKINJE CELL; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA;

EID: 52249098578     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp27309     Document Type: Article

References (32)

1. Abe H, Yagishita S, Amano N, Iwabuchi K, Hasegawa K, Kowa K. Argyrophilic glial intracytoplasmic inclusions in multiple system atrophy: immunocytochemical and ultrastructural study. Acta Neuropathol (Berl). 1992; 84: 273-277.
2. Arai N, Nishimura M, Oda M, Morimatsu Y, Ohe R, Nagatomo H. Immunohistochemical expression of microtubule-associated protein 5 (MAP5) in glial cells in multiple system atrophy. J Neurol Sci. 1992; 109: 102-106.
3. Arima K, Murayama S, Mukoyama M, Inose T. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 1. Neuronal cytoplasmic inclusions. Acta Neuropathol (Berl). 1992; 83: 453-460.
4. Baum L, Hansen L, Masliah E, Saitoh T. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Mol Chem Neuropathol. 1996; 29: 253-261.
5. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC Jr, Nairn AC, Greengard P. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999; 402: 669-671.
6. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000; 12: 676-684.
7. Fienberg AA, Greengard P. The DARPP-32 knockout mouse. Brain Res Brain Res Rev. 2000; 31: 313-319.
8. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst. 1998; 74: 189-192.
9. Griffin SV, Hiromura K, Pippin J, Petermann AT, Blonski MJ, Krofft R, Takahashi S, Kulkarni AB, Shankland SJ. Cyclin-dependeut kinase 5 is a regulator of podocyte differentiation, proliferation, and morphology. Am J Pathol. 2004; 165: 1175-1185.
10. Honjyo Y, Kawamoto Y, Nakamura S, Nakano S, Akiguchi I. Immunohistochemical localization of CDK5 activator p39 in the rat brain. Neuroreport. 1999; 10: 3375-3379.
11. Honjyo Y, Kawamoto Y, Nakamura S, Nakano S, Akiguchi I. P39 immunoreactivity in glial cytoplasmic inclusions in brains with multiple system atrophy. Acta Neuropathol (Berl). 2001; 101: 190-194.
12. Kato S, Nakamura H, Hirano A, Ito H, Llena JF, Yen SH. Argyrophilic ubiquitinated cytoplasmic inclusions of Leu-7-positive glial cells in olivopontocerebellar atrophy (multiple system atrophy). Acta Neuropathol (Berl). 1991; 82: 488-493.
13. Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, Wang JH. A brain-specific activator of cyclin-dependent kinase 5. Nature. 1994; 29: 423-426.
14. Lindersson E, Lundvig D, Petersen C, Madsen P, Nyengaard JR, Hojrup P, Moos T, Otzen D, Gai WP, Blumbergs PC, Jensen PH. P25α stimulates α-synuclein aggregation and is colocalized with aggregated α-synuclein in α-synucleinopathies. J Biol Chem. 2005; 280: 5703-5715.
15. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E, Tsai LH. A family of human cdc2-related protein kinases. EMBO J. 1992; 11: 2909-2917.
16. Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J. p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol (Berl). 1997; 94: 153-157.
17. Nakamura S, Kawamoto Y, Nakano S, Ikemoto A, Akiguchi I, Kimura J. Cyclin-dependent kinase 5 in Lewy body-like inclusions in anterior horn cells of a patient with sporadic amyotrophic lateral sclerosis. Neurology. 1997; 48: 267-270.
18. Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J. Cyclin-dependent kinase 5 and mitogen-activated protein kinase in glial cytoplasmic inclusions in multiple system atrophy. J Neuropathol Exp Neurol. 1998; 57: 690-698.
19. Nishie M, Mori F, Yoshimoto M, Takahashi H, Wakabayashi K. A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. J Neuropathol Appl Neurobiol. 2004; 30: 546-554.
20. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA. 1996; 1: 11173-11178.
21. Ouimet CC, Miller PE, Hemmings HC Jr, Walaas SI, Greengard P. DARPP-32, a dopamine- and adenosine 3′5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J Neurosci. 1984; 4: 111-124.
22. Paglini G, Pigino G, Kunda P, Morfini G, Maccioni R, Quiroga S, Ferreira A, Caceres A. Evidence for the participation of the neuron-specific CDK5 activator P35 during laminin-enhanced axonal growth. J Neurosci. 1998; 18: 9858-9869.
23. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989; 94: 79-100.
24. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. 1994; 117: 235-243.
25. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999; 402: 588-589.
26. Reed SI. Control of the G1/S transition. Cancer Surv. 1997; 29: 7-23.
27. Sengupta A, Wu Q, Grundke-Iqbal I, Iqbal K, Singh TJ. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human τ by cdk5. Mol Cell Biochem. 1997; 167: 99-105.
28. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004; 44: 269-296.
29. Takahashi M, Iseki E, Kosaka K. Cdk5 and munc-18/p67 co-localization in early stage neurofibrillary tangles-bearing neurons in Alzheimer type dementia brains. J Neurol Sci. 2000; 1: 63-69.
30. Tang XM, Strocchi P, Cambi F. Changes in the activity of cdk2 and cdk5 accompany differentiation of rat primary oligodendrocytes. J Cell Biochem. 1998; 68: 128-137.
31. Xiong W, Pestell R, Rosner MR. Role of cyclins in neuronal differentiation of immortalized hippocampal cells. Mol Cell Biol. 1997; 17: 6585-6597.
32. Wakabayashi K, Takahashi H. Cellular pathology in multiple system atrophy. Neuropathology. 2006; 26: 338-345.